Ausgabe 10/2015
Inhalt (11 Artikel)
Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness
Aaron S. Kesselheim, Joshua J. Gagne
Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update
Maartje N. Niemeijer, Marten E. van den Berg, Mark Eijgelsheim, Peter R. Rijnbeek, Bruno H. Stricker
Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis
Alice Capogrosso Sansone, Stefania Mantarro, Marco Tuccori, Elisa Ruggiero, Sabrina Montagnani, Irma Convertino, Alessandra Marino, Matteo Fornai, Luca Antonioli, Tiberio Corona, Danila Garibaldi, Corrado Blandizzi
Photosensitivity with Angiotensin II Receptor Blockers: A Retrospective Study Using Data from VigiBase®
Ermelinda Viola, Anna Coggiola Pittoni, Agnes Drahos, Ugo Moretti, Anita Conforti
A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions
Ying Li, Patrick B. Ryan, Ying Wei, Carol Friedman
Benzodiazepine Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis
Patrick Imfeld, Michael Bodmer, Susan S. Jick, Christoph R. Meier
Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies
Preciosa M. Coloma, Benedikt Becker, Miriam C. J. M. Sturkenboom, Erik M. van Mulligen, Jan A. Kors
Comment on: “Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study from Ethiopia”
Mark Cotton, Simone Nicol
Authors’ Reply to Cotton and Nicol’s Comment on “Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study from Ethiopia”
Woldesellassie M. Bezabhe, Luke R. Bereznicki, Leanne Chalmers, Peter Gee, Desalew M. Kassie, Mekides A. Bimirew, Gregory M. Peterson